Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
ALBI Grade (Liver)ASTCT GradingATA Thyroid RiskBCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPICML ELTS ScoreCNS-IPICTCAE v5.0Calvert FormulaDIPSS-Plus (Myelofibrosis)Deauville ScoreEAU NMIBC RiskECOG Performance StatusELN 2022 Risk (AML)ELN CML MilestonesFIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2Fleischner 2017 GuidelinesFong Clinical Risk ScoreHCT-CI (Sorror Score)HPV/p16 OropharynxIGCCCG Risk (Testicular)IMDC (Heng) CriteriaIMWG Myeloma FrailtyIPSS-M (Molecular MDS)ISUP Grade GroupsKarnofsky Status (KPS)Khorana ScoreLugano ClassificationLung-RADS v2022MIPI-b (Biological)MRD Assessment FrameworkMSI/MMR InterpretationMayo 20/2/20 (SMM)NCCN Prostate RiskNCCN-IPI (DLBCL)NSCLC GPAOncotype DX RecurrenceOpioid EquianalgesicPD-L1 TPS InterpretationPERCIST 2.0PREDICT v3.0Platinum-Free IntervalR2-ISS (Revised 2)RANO 2.0RCB (Residual Cancer Burden)RECIST 1.1ROMA ScoreSAVER ScoreSINS ScoreSLiM-CRAB CriteriaSedlis/Peters CriteriaTNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AMLZ0011 EligibilityiRECISTiwCLL 2018 ResponsemRECIST (HCC)mRENAL ScoremrTRG (Rectal MRI)
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Recent Journal Updates

DiabetologiaJun 8, 2026
Genetics of MASLD: a diabetes perspective

Clinical Context

We think this might be relevant to the clinical guidance for PERCIST 2.0 (PET Response Criteria).

Intensive Care MedicineJun 8, 2026
International evidence-based recommendations for point-of-care lung ultrasound

Clinical Context

We think this might be relevant to the clinical guidance for PERCIST 2.0 (PET Response Criteria).

Cancer MedicineJun 8, 2026
Exploring the High‐Risk Factors of Gastric “Inflammatory Cancer Transformation” Based on Inflammatory Immune Response: Construction of RHPI Complicated With CAG Risk Prediction Model

Clinical Context

We think this might be relevant to the clinical guidance for PERCIST 2.0 (PET Response Criteria).

PERCIST 2.0

PERCIST 2.0Metabolic Response Criteria (FDG-PET)

Metabolic Category

Clinical pearl

PERCIST relies on SUL (SUV normalized to lean body mass) rather than standard SUV to reduce variability between scans. A decrease in SULpeak is the primary metric for response.

Metabolic Outlook

SMD

Clinical Strategy

Stable Metabolic Disease. Neither sufficient decrease to qualify for PMR nor sufficient increase to qualify for PMD.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Evaluating response in highly FDG-avid tumors (e.g., NSCLC, Melanoma, Colorectal cancer).
Differentiating viable tumor from post-treatment fibrosis or scarring (where RECIST 1.1 often falsely calls "Stable Disease").
Used heavily in early-phase clinical trials to establish proof-of-concept for novel cytostatic agents.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the RECIST 1.1, Deauville Score Interpreter or the iRECIST to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Oncology Tools

RECIST 1.1
Deauville Score Interpreter
iRECIST
RANO 2.0
Mayo 20/2/20
Opioid Equianalgesic
NCCN-IPI
HPV/p16 Oropharynx
SLiM-CRAB Criteria
Fong Clinical Risk Score
Oncology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.